The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/174452

Please be advised that this information was generated on 2020-03-10 and may be subject to change.
The Parelsnoer Institute (PSI) is a collaborative biobanking project of all eight University Medical Centers in the Netherlands which was launched in 2007. Basically, PSI consists of three dimensions: participating institutions, disease entities and a central organization. An executive board for operational management instigates collective strategic and tactic policies and a central team of PSI experts and advisors supports the researchers and the board in establishing and implementing standards and procedures. PSI offers researchers an infrastructure and standard procedures for the establishment, expansion and optimisation of clinical biobanks for scientific research. To ensure patient privacy clinical data is pseudomized and carefully stored in a central database. Human biomaterials are collected according to nationally agreed standards.

Currently PSI covers fifteen large disease specific cohorts (the so-called ‘Parels’ or ‘Pearls’) and new ‘Pearls’ are being developed. The Parelsnoer Institute currently (December 2016) has stored more than 538,000 biospecimens with annotated clinical data of more than 30,000 patients. All these materials and data are available for anyone with a bona fide research proposal.

Keywords: Harmonized standards; clinical biobanking; translational medical research; health innovation; generic information architecture; international security and privacy standards

Funding statement: PSI started in 2007 with a five year initial grant from the Dutch Government. From 2011 onwards PSI is supported and facilitated by the Netherlands Federation of University Medical Centers (NFU) and its member institutions. This means that sustainability of PSI as core infrastructure for applied clinical research in the Netherlands is not dependent on external funds. Additional funds from charities, governmental sources and industrial sponsors are used to expand PSI with new disease groups and for the analyses of the collections in actual research projects.
Each UMC stores biomaterials in their own certified biobank(s) according to the PSI biobanking protocol, which was developed by biobank coordinators from all UMCs together and covers all phases of biobanking. Each Pearl provides a different variety of biomaterials such as serum, plasma, DNA, faeces, urine, cerebrospinal fluid, pancreatic cyst fluid, viable cells, fresh frozen tissues and/or FFPE tissues. Metadata (e.g., type of material) from biomaterials and the unique sample code are registered in the central database together with the clinical data [18].

For each Pearl a specific information model is defined for the detailed clinical dataset including personal data and clinical data pertaining the specific disease [19]. The data are collected both via electronic and manual methods and are hosted in a validated web based application (ProMISe) that fulfills international standards for data management, quality assurance, and privacy protection using a Trusted Third Party [20, 21].

**Classification (1)**
Human.

**Classification (2)**
Biological samples and associated clinical data.

**Context**

**Spatial coverage**
Description:
All eight University Medical Centers across the Netherlands: Academic Medical Center (Amsterdam), Erasmus Medical Center (Rotterdam), Leiden University Medical Center, Maastricht University Medical Center, Radboud University Medical Center (Nijmegen), University Medical Center Groningen, University Medical Center Utrecht, VU University Medical Center (Amsterdam).

Northern boundary: +53.4647366.
Southern boundary: +50.757197.
Eastern boundary: +7.222824.
Western boundary: +3.364563.

**Temporal coverage**
Eight disease-specific bioresources started their collection in 2009. Five others started later and new collections will start in the (near) future. The end date might differ between the collections, however, so far no expected end date has been determined for any collection.

**Temporal coverage for accessibility**
The bioresources are available for use in bona fide research projects; no end date determined.
(2) Methods

Steps
For each Pearl a specific information model is defined, called PRISMA: Parelsnoer Repository for Information Specification, Modelling and Architecture. PSI adheres to the principle of reusing electronic health record (EHR) information for scientific purposes (“registration at the source”, [http://www.nfu.nl/programma/registratie-aan-de-bron/programma](http://www.nfu.nl/programma/registratie-aan-de-bron/programma)). Therefore, PRISMA is developed with reuse of information and with minimization of registration burden as prime directives, while also taking routine care procedures into account. The architecture is in compliance with (inter-)national classifications such as International Classification of Diseases and Related Health Problems (ICD-10), SNOMED CT and the Logical Observation Identifiers Names and Codes (LOINC®).

Each Pearl defines its own set of biosamples to be collected and stored in the biobank. Biomaterials are preferably collected during routine clinical procedures. Samples are stored in certified UMC biobanking facilities which collectively constitute the federative PSI biobank. The biobanking protocol of PSI is implemented in all the participating institutions and covers all phases of biobanking; from collection to storage of

| Sample                      | Volume/number | Processing                                               | Time                     | Aliquoting                  | Storage            |
|-----------------------------|---------------|----------------------------------------------------------|--------------------------|-----------------------------|--------------------|
| Serum                       | 10 ml clotted blood | 2000 × g at room temperature or 4°C for 10 minutes | Within 2–4 hours         | ≥ 5 × 0.5 ml                | –80°C              |
| EDTA plasma                 | 10 ml         | 2000 × g at room temperature or 4°C for 10 minutes      | Within 2–4 hours         | ≥ 5 × 0.5 ml                | –80°C              |
| Citrate plasma              | 9 ml          | 2000 × g at room temperature for 10 minutes             | Within 2–4 hours         | ≥ 5 × 0.5 ml                | –80°C              |
| DNA (blood)                 | 10 ml EDTA blood | Whole blood or cell pellet, to UMC specifications       | Within 4 weeks (4°C) or 3 months (< −20°C) | ≥ 2 stock aliquots       | 4°C or lower       |
| Faeces                      | Not specified | Direct storage or after homogenization                  | Within 12 hours          | ≥ 5 × 5 gr                 | −80°C              |
| Urine +/- antioxidants (AO) | Not specified, midstream | 2000 × g at room temperature or 4°C (AO) for 10 minutes | Within 4 hours          | 6 aliquots 0.9 ml         | −80°C              |
| Cerebrospinal fluid         | 3–20 ml       | 2000 × g at room temperature or 4°C for 10 minutes     | Within 2 hours           | ≥ 6 × 0.5 ml                | −80°C in polypropylene tubes |
| Biopsy FFPE                 | n* per location# | Formalin fixation and paraffin embedding               | Immediate fixation       | Per set                     | Room temperature |
| Biopsy frozen               | n* per location# | Snap frozen in isopentane                               | Immediate                | Per set                     | −80°C              |
| Resection specimen FFPE     | n* per location# | Snap frozen in isopentane                               | At pathology             | 0.5 cm³ samples             | Room temperature |
| Resection specimen frozen   | n* per location# | Snap frozen in isopentane                               | At pathology             | 0.5 cm³ samples             | −80°C              |
| Pancreatic cyst fluid       | ≥ 0.5 ml      | None                                                     | Within 2–4 hours         | 0.5 ml portions             | −80°C              |
| Viable cells (PBMCs or bone marrow) | 20–40 ml heparinized sample | Density centrifugation at room temperature             | Within 24 hours          | 10 × 10⁶ cells per cryovial | −130°C            |

Table 1: Summary of procedures on collection, processing and storage of samples defined in the biobanking protocol of PSI.

† Deviations to be registered: hemolytic, lipemic, icteric, wrong tube, volume incorrect, storage temperature deviation, longer storage time, mixing/homogenization incorrect, centrifugation process different, storage problem, other deviation as free text.

* as specified by Pearl.

# for instance normal or affected or inflamed or tumor in intestinal tract or skin.

PBMCs: peripheral blood mononuclear cells.
the samples. Metadata (e.g., type of material) from biomaterials and the unique sample code are registered in the central database together with the clinical data. The detailed clinical dataset includes personal data (e.g., age, gender, education level, ethnic origin, weight, height) and clinical data pertaining the specific disease (e.g., diagnosis, lab results, complications, physical examination, (medical) treatment, questionnaires). The data are collected both via electronic and manual methods and are hosted in a validated web based application (ProMiSe) [20].

PSI also provides an infrastructure and procedures to uniformly collect and store images, for instance MRI images. Standardized source images are safely stored in the local Picture Archive and Communication System (PACS) in the UMCs. After anonymization, the images are subsequently uploaded in the TraIT Bio-Medical Imaging Archive (BMIA), which is a safe and sustainable online archive [22].

Stabilization/preservation

Table 1 gives a summary of procedures on collection, processing and storage of samples defined in the biobanking protocol of PSI.

Type of long-term preservation
See Table 1.

Storage temperature
See Table 1.

Shipping temperature from patient/source to preservation or research use
See Table 1.

Shipping temperature from storage to research use

–80°C (on dry ice).

Quality assurance measures

Quality of data and quality of stored biomaterials are by no means self-evident. In PSI, the two most important critical success factors for adequate data quality are: to limit the number of elements in the information model to what is necessary for future research and to fully integrate the collection of data in the routine of the EHR. Other essential elements for adequate quality are: use international standards (Detailed Clinical Models), develop simple and logical instructions for data collection and registration, mandate and authorize dedicated research employees, and perform regular quality checks.

For biomaterials there is no possibility to improve quality afterwards. Only a strict adherence to the biobank protocol and related SOPs can assure quality of material available for research. This is under the assumption that SOPs describe (either evidence or consensus based) what is optimal for integrity of the biomaterials. In PSI, biobank coordinators from all UMCs together have developed the PSI biobanking protocol and revise them every two years. This involvement of all biobank coordinators in establishing the protocol enhances adherence to the described procedures. The PSI biobanking protocol covers all phases of biobanking: collection, pre-analysis, registration, processing and storage of the samples (Table 1).

Source of associated data

The associated data are mainly coming from electronic health records, laboratory reports, and questionnaires. Each UMC has its own research IT infrastructure that

Figure 2: IT Infrastructure of PSI.
delivers the data to their local database in ProMISe, which is a web based application. In some UMCs data are entered manually into the local database (mostly by research nurses and/or clinicians) while other UMCs benefit from automatic data capture directly from the EHR resources. The information supplied by each UMC is periodically uploaded, after validation, to the central database in ProMISe (one database per Pearl, which is the combination of the 8 local UMC Pearl databases) for storage on a national level (Figure 2). During upload of data to the local and central databases, identifying data are encrypted by special software of a Trusted Third Party (Trusted Reversible Encryption Service®, Houten, Utrecht, The Netherlands). As to further protect the privacy of the patients, the identifying data are encrypted again when exported from the central database for delivery to the researchers. In specific situations, e.g., in case of incidental findings that need feedback to the patient or necessary data-linkage, depseudonymization is possible by authorized personnel only. The PSI IT infrastructure is compliant with international security and privacy standards.

### (3) Bioresource description

**Object name**
The Parelsnoer Institute.

**Bioresource name**
The Parelsnoer Institute (PSI).

**Bioresource location**
All eight University Medical Centers across the Netherlands participate in PSI:

1. Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
2. Erasmus Medical Center, ’s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
3. Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
4. Maastricht University Medical Center, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands
5. Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands
6. University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
7. University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
8. VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

**Bioresource contact**
Parelsnoer Institute, Jaarbeursplein 6, 3521 Al Utrecht, The Netherlands.
Email: info@parelsnoer.org

**Bioresource URL**
http://parelsnoer.org/page/en/Home.

**Identifier used**
N/A.

**Bioresource type**
PSI is a collaborative clinical biobank, comprising a number of disease specific national bioresources (the Pearls). All types of pathology and disease samples are stored (see Table 1). To date (October 2016) the following fifteen disease categories are included:

- Abdominal aortic aneurysm
- Congenital heart disease
- Cerebrovascular accident
- Diabetes
- Hereditary colorectal cancer
- Inflammatory bowel disease
- Ischemic heart disease
- Leukemia, myeloma and lymphoma
- Multiple endocrine neoplasia
- Neurodegenerative diseases
- Oesophageal and gastric cancer
- Pancreatic cancer and pancreatitis
- Renal failure
- Rheumatoid arthritis and arthrosis
- Parkinson’s disease

**Type of sampling**
PSI consists of disease based cohorts with longitudinal collections, sampled in clinical care.

**Anatomical site**
The fifteen Pearls cover several anatomical sites of the human body.

**Disease status of patients/source**
See the fifteen Pearls/diseases mentioned above.

**Clinical characteristics of patients/source**
A full clinical characterization, including extensive diagnostics, demographics, therapeutics and clinical follow-up is specified for each disease specific bioresource.

**Vital state of patients/source**
All patients are alive at inclusion.

**Clinical diagnosis of patients/source**
PSI covers several significant diseases, presently fifteen: Abdominal aortic aneurysm, Congenital heart disease, Cerebrovascular accident, Diabetes, Hereditary colorectal cancer, Inflammatory bowel disease, Ischemic heart disease, Leukemia, myeloma and lymphoma, Multiple endocrine neoplasia, Neurodegenerative diseases, Oesophageal and gastric cancer, Pancreatic cancer and pancreatitis, Renal failure, Rheumatoid arthritis and arthrosis, Parkinson’s disease.

**Pathology diagnosis**
The architecture is in compliance with (inter-)national classifications such as International Classification of Diseases and Related Health Problems (ICD-10), SNOMED.
CT and the Logical Observation Identifiers Names and Codes (LOINC®).

**Control samples**

The Parelsnoer Institute does not collect control samples from healthy individuals. If needed controls can be obtained from LifeLines, a national longitudinal population biobank in the Netherlands [24].

**Biospecimen type**

Each Pearl provides a different variety of biomaterials such as serum, plasma, DNA, RNA, faeces, urine, cerebrospinal fluid, pancreatic cyst fluid, viable cells, fresh frozen tissues and/or FFPE tissues. Table 1 gives a summary of procedures on collection, processing and storage of samples defined in the biobanking protocol of PSI.

**Size of the bioresource**

In total, clinical data of more than 32,000 patients and 538,000 biospecimens of more than 30,000 patients are available. PSI has no end date. The current number of included patients per Pearl is shown in Table 2.

**Release date**

Data and samples are currently available. PSI releases data and samples to research projects on a regular basis. Thus far, the research projects have led to many scientific publications [3–17].

**Access criteria**

A catalogue, i.e., an open access searchable database on the internet, provides up-to-date information about the content of all PSI collections [18]. This gives researchers the opportunity to discover for what type of patients which type and amount of data and biomaterials are available. Every researcher worldwide may submit a study proposal to the Pearl and request data, biomaterials and/or images.

A scientific committee of the Pearl (consisting of representatives of the Pearl and independent scientific experts) judges whether the proposed study is relevant, compliant with the scientific aims of the Pearl, methodologically sound, compliant with privacy protection rules and feasible in relation to the amount of biomaterial requested. In addition, permission from the Research Ethical Committee of the coordinating UMC has to be obtained and from some other participating centers according to local policy. When permissions have been granted and request forms are completed, the PSI data manager will deliver the data (and images if needed) from the central PSI facilities to the researcher. The biobank coordinators of the UMCs will deliver the requested biomaterials. If scientific analyses in research projects yield new data, PSI demands these newly acquired (individual) data to be made available for future research purposes.

Costs vary depending on the type and amount of samples. An economic quotation is sent covering shipping costs and partially costs for biobanking-related services (sample handling, consumables).

### Table 2: The number of included patients per Pearl.*

* dd December 12, 2016.

† Three Pearls (i.e., Multiple Endocrine Neoplasia, Abdominal Aortic Aneurysm and Parkinson’s Disease) started recently and to date (December 2016) have not yet included patients.

| Pearl†       | Number of patients with clinical data | Number of patients with biomaterials |
|--------------|---------------------------------------|--------------------------------------|
| Congenital heart disease | 5400                                  | 5400                                 |
| Cerebrovascular accident  | 5815                                  | 5374                                 |
| Diabetes      | 6673                                  | 6226                                 |
| Hereditary colorectal cancer | 1853                                  | 1534                                 |
| Inflammatory bowel disease | 4642                                  | 4139                                 |
| Ischemic heart disease   | 632                                   | 412                                  |
| Leukemia, myeloma and lymphoma | 1755                                  | 1596                                 |
| Neurodegenerative disease | 1213                                  | 1122                                 |
| Esophageal and gastric cancer | 122                                   | 93                                   |
| Pancreatic cancer and pancreatitis | 318                                   | 282                                  |
| Renal failure           | 1991                                  | 1963                                 |
| Rheumatoid arthritis and arthrosis | 2277                                  | 2190                                 |

(4) Reuse potential

Samples from the same donor may be used in several different projects. As a condition of supply of material, the recipient of samples and/or data must agree to return findings to PSI on conclusion of the research purpose. These newly acquired (individual) data are then available for future research purposes. Besides, the applicant must...
acknowledge PSI in all publications resulting from the use of these data and samples and provide a copy of the published paper to PSI.

**Ethics Statement**

PSI provides a regulatory framework in which ethical guidelines, in accordance with (inter-)national legislation and rules, are described [23]. Supported by a member of the PSI Central Team, each Pearl complies with these guidelines and is reviewed by the Medical Ethical Committee. Subsequently, Medical Ethical Committees and Board of Directors of the remaining participating UMCs to approve local implementation of the Pearl’s biobanking activities. Patients included in the Pearl give written informed consent prior to inclusion.

**Constraints**

Only patients who provided written informed consent are included, no healthy controls. Participants may withdraw their consent at all times. The patient can express the wish to withdraw to his/her doctor, in which case the doctor will ensure that data and materials are destroyed unless needed for validation of earlier issuance.

**Competing Interests**

The authors have no competing interests to declare.

**Author Roles**

Judith Manniën: PSI Data Manager
Tessa Ledderhof: PSI Operational Manager
Hein Verspaget: PSI Bioresource Manager
Roger Snijder: PSI Information Architect
Erik Flikkenschild: PSI ICT Coordinator and Privacy-Security Officer
Nicole van Scherrenburg: PSI Management Assistant
Ronald Stolk: member of PSI Board
Gerhard Zielhuis: PSI Managing Director

**References**

1. Parelsnoer Institute 2016 http://parelsnoer.org/page/en/ (accessed October 14, 2016).
2. Boeckhout, M, Reuzel, R and Zielhuis, G 2014 The donor as partner. How to involve patients and the public in the governance of biobanks and registries. Leiden: BBMRI-NL.
3. Aalten, P, Ramakers, I H and Biessels, G J et al 2014 The Dutch Parelsnoer Institute-Neurodegenerative diseases; methods, design and baseline results. BMC Neuro; 14: 254. DOI: https://doi.org/10.1186/s12883-014-0254-4
4. Haverkamp, L, Parry, K and van Berge Henegouwen, M I et al 2016 Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands. Dis Esophagus; 29: 435–441. DOI: https://doi.org/10.1111/dote.12347
5. Navis, G J, Blankestijn, P J and Deegens, J et al 2014 The Biobank of Nephrological Diseases in the Netherlands cohort: the String of Pearls Initiative collaboration on chronic kidney disease in the university medical centers in the Netherlands. Nephrol Dial Transplant; 29: 1145–1150. DOI: https://doi.org/10.1093/ndt/gft307
6. van Nederkoon, P J, Dijkstra, E J and Koudstaal, P J et al 2015 The Dutch String-of-Pearls Stroke Study: protocol of a large prospective multicenter genetic cohort study. Int J Stroke; 10: 120–122. DOI: https://doi.org/10.1111/ijs.12359
7. van’t Riet, E, Schram, M T and Abbink, E J et al 2012 The Diabetes Pearl: Diabetes biobanking in The Netherlands. BMC Public Health; 12: 949. DOI: https://doi.org/10.1186/1471-2458-12-949
8. Visschedijk, M C, Alberts, R and Mucha, S et al 2016 Pooled resequencing of 122 ulcerative colitis genes in a large Dutch cohort suggests population-specific associations of rare variants in MUC2. PLoS One;11(8): e0159609. DOI: https://doi.org/10.1371/journal. pone.0159609
9. Van Wier, M F, Huizinga, T W J and Brouwer, E et al 2016 [The Rheumatoid Arthritis and Arthritis Pearl: the biobank for early arthritis patients of the Dutch UMCs.] Ned Tijdschr Reumatol; 2: 32–39.
10. Velde, E T, Vriend, J W and Mannens, M M et al 2005 CONCOR, an initiative towards a national registry and DNA-bank of patients with congenital heart disease in the Netherlands: rationale, design, and first results. Eur J Epidemiol; 20: 549–57. DOI: https://doi.org/10.1007/s10654-005-4264-9
11. Vriend, J W, van der Velde, E T and Mulder, B J 2004 National registry and DNA-bank of patients with congenital heart disease: the CONCOR-project. Ned Tijdschr Geneeskd; 148: 1646–1647.
12. Schoormans, D, Sprangers, M A and van Melle, J P et al 2016 Clinical and psychological characteristics predict future healthcare use in adults with congenital heart disease. Eur J Cardiovasc Nurs; 15(1): 72–81. DOI: https://doi.org/10.1177/1474515114555819
13. Sluman, M A, Apers, S and Bouma, B J et al 2015 Uncertainties in insurances for adults with congenital heart disease. Int J Cardiol; 186: 93–95. DOI: https://doi.org/10.1016/j.ijcard.2015.03.208
14. Kuijpers, J M, van der Bom, T and van Riel, A C et al 2015 Secundum atrial septal defect is associated with reduced survival in adult men. Eur Heart J; 36(31): 2079–2086. DOI: https://doi.org/10.1093/eurheartj/ehv097
15. Luijendijk, P, Lu, H and Heyneman, F B et al 2014 Increased carotid intima-media thickness predicts cardiovascular events in aortic coarctation. Int J Cardiol; 176(3): 776–781. DOI: https://doi.org/10.1016/j. ijcard.2014.07.090
16. Koyak, Z, Kroon, B and de Groot, J R et al 2013 Efficacy of antiarrhythmic drugs in adults with congenital heart disease and supraventricular tachycardias. Am J Cardiol; 112(9): 1461–1467. DOI: https://doi.org/10.1016/j.amjcard.2013.07.029
17. van Slooten, Y J, Freling, H G and van Melle, J P et al 2014 Long-term tricuspid valve prothesis-related complications in patients with congenital heart
disease. *Eur J Cardiothorac Surg*, 45(1): 83–89. DOI: https://doi.org/10.1093/ejcts/ezt259

18. **Catalogue of the Parelsnoer Institute** 2016 www.parelsnoer.org/page/en/Catalogue (accessed September 27, 2016).

19. **Talmon, J L, Ros, M G and Legemate, D A** 2008 The Dutch Academic Infrastructure for shared biobanks for translational research. Summit on Translat Bioinforma; 2008: 110–4.

20. **ProMISe (Project Manager Internet Service)** 2016 https://www.msbi.nl/promise/ (accessed October 14, 2016).

21. **ZorgTTP** 2016 https://www.zorgttpl.nl/ (accessed October 14, 2016).

22. **BMIA, The TraIT Bio-Medical Imaging Archive.** 2016. www.ctmm-trait.nl/work-packages/work-package-2-biomedical-imaging (accessed September 27, 2016).

23. **Boeckhout, M, Van Dijk, J and Legemate, D A** 2011 [Ethical review of biobanks in The Netherlands: lessons from the String of Pearls Initiative]. *Ned Tijdschr Geneeskd*; 155: A3557.

24. **Lifelines** 2016 https://lifelines.nl/lifelines-research/general (accessed October 14, 2016).